The Federal Trade Commission has approved Allergan's ( AGN - Get Report) proposed acquisition of Inamed ( IMDC), a health care company. This approval was the final antitrust approval required for the acquisition.

Allergan confirmed the expiration time for the offer is Friday. Allergan is offering $84 in cash, or 0.8498 share of Allergan for each outstanding share of Inamed. As per the offer, 45% of Inamed shares tendered will be exchanged for cash and 55% will get Allergan stock.

"We are pleased to have received U.S. antitrust approval from the FTC, and we look forward to rapidly completing the Inamed acquisition so we can initiate our integration plan," Allergan said. "We expect to finalize the acquisition as promptly as possible after the exchange offer is completed."

This story was created through a joint venture between and IRIS.